Skip to main content
FinSpry Logo
FinSpry
CORT logo
CORT
(NASDAQ)
Corcept Therapeutics Incorporated
$42.49-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Corcept Therapeutics Incorporated (CORT) Stock Price & Financial Analysis

Corcept Therapeutics Incorporated Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$40.48 - $43.37
52-Week High$91.00
52-Week Low$28.66
Open$40.95
Volume1.50M
Average Volume (3M)1.50M
Market Cap5.10B
Shares Outstanding119.99M
P/E Ratio (TTM)50.55
Forward P/E71.55
Price to Sales (P/S)6.62
Price to Book (P/B)7.78
EV/EBITDA94.47
Revenue (TTM)761.41M
Net Income (TTM)99.65M
Free Cash Flow (TTM)141.78M
EPS (TTM)$0.83
Profit Margin13.09%
Operating Margin5.88%
Return on Equity (ROE)15.38%
Debt to Equity0.01
50-Day MA$37.74
200-Day MA$63.56
52-Week Change-54.33%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Corcept Therapeutics Incorporated

What is the current stock price for CORT?

As of the latest trading session, CORT stock trades at $42.49. The 52-week range is $28.66–$91.00, with a day range of $40.48–$43.37.

What is the P/E ratio for CORT?

Corcept Therapeutics Incorporated's trailing P/E ratio is 50.5, meaning investors pay $50.5 for every $1 of annual earnings. The forward P/E is 71.5, reflecting analyst expectations for future earnings. Corcept Therapeutics Incorporated operates in the Healthcare sector.

Does CORT pay dividends?

Corcept Therapeutics Incorporated does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for CORT?

Based on 3 analysts, the consensus for CORT is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of CORT?

Corcept Therapeutics Incorporated's market capitalization is $5.10B, classifying it as a mid-cap company. Corcept Therapeutics Incorporated operates in the Healthcare sector within the Biotechnology industry.